Venus Medtech (Hangzhou) (HKSE:02500) Change In Receivables : HK$15.5 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Change In Receivables?

Venus Medtech (Hangzhou)'s change in receivables for the quarter that ended in Dec. 2023 was HK$132.9 Mil. It means Venus Medtech (Hangzhou)'s Accounts Receivable declined by HK$132.9 Mil from Jun. 2023 to Dec. 2023 .

Venus Medtech (Hangzhou)'s change in receivables for the fiscal year that ended in Dec. 2023 was HK$15.5 Mil. It means Venus Medtech (Hangzhou)'s Accounts Receivable declined by HK$15.5 Mil from Dec. 2022 to Dec. 2023 .

Venus Medtech (Hangzhou)'s Accounts Receivable for the quarter that ended in Dec. 2023 was HK$317.9 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Venus Medtech (Hangzhou)'s Days Sales Outstanding for the six months ended in Dec. 2023 was 224.95.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Venus Medtech (Hangzhou)'s liquidation value for the six months ended in Dec. 2023 was HK$-479.4 Mil.

Venus Medtech (Hangzhou) Change In Receivables Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Change In Receivables Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-96.92

-83.93

-116.84

-12.16

15.54

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial							52.45	-44.25	30.00	-117.32	132.86

Venus Medtech (Hangzhou) Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$15.5 Mil.

Venus Medtech (Hangzhou) (HKSE:02500) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Venus Medtech (Hangzhou)'s Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	317.86	/	257.873	*	91
=	224.95

2. In Ben Graham's calculation of liquidation value, Venus Medtech (Hangzhou)'s accounts receivable are only considered to be worth 75% of book value:

Venus Medtech (Hangzhou)'s liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	854.937	-	1634.508	+	0.75 * 317.86	+	0.5 * 123.534
=	-479.4

Venus Medtech (Hangzhou) Change In Receivables Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (HKSE:02500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VMTHF:USA

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) (HKSE:02500) Headlines

No Headlines